Cargando…

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study

INTRODUCTION: Immune checkpoint inhibitors (ICIs) have demonstrated promising efficacy as monotherapy in patients with pulmonary sarcomatoid carcinoma (PSC). We performed the current multi-institutional, real-world study to assess the efficacy of ICIs plus chemotherapy in patients with PSC. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Fei, Guo, Haoyue, Zhou, Xiaolong, Xie, Huikang, Tian, Tian, Zhao, Wencheng, Gao, Guanghui, Xiong, Anwen, Wang, Lei, Li, Wei, Chen, Xiaoxia, Zhang, Yan, Fan, Jue, Wu, Fengying, Zhang, Yongchang, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676284/ https://www.ncbi.nlm.nih.gov/pubmed/36419724 http://dx.doi.org/10.1177/17588359221136759

Ejemplares similares

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study
por: Dimitrakopoulos, Foteinos-Ioannis, et al.
Publicado: (2022)

A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)
por: Shibaki, Ryota, et al.
Publicado: (2021)

The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
por: Low, Jia Li, et al.
Publicado: (2019)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study
por: Ikeda, Satoshi, et al.
Publicado: (2020)

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
por: Cinausero, Marika, et al.
Publicado: (2019)

Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)

Effect of immunotherapy on overall survival in limited-stage small cell lung carcinoma: a national cancer database analysis
por: Bilani, Nadeem, et al.
Publicado: (2021)

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
por: Gristina, Valerio, et al.
Publicado: (2021)

Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients
por: Gkountakos, Anastasios, et al.
Publicado: (2021)

Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
por: Xuzhang, Wendi, et al.
Publicado: (2023)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

Distribution and characterization of microplastics in marine sediments from the Montenegrin coast
por: Bošković, Neda, et al.
Publicado: (2022)

The impact of COVID-19 on tuberculosis: challenges and opportunities
por: Kant, Surya, et al.
Publicado: (2021)

Bronchial brushing Xpert improves the diagnostic efficiency of sputum Xpert in patients with pulmonary tuberculosis
por: He, Yu, et al.
Publicado: (2021)

The role of bronchoscopy in the diagnosis and management of pediatric pulmonary tuberculosis
por: Goussard, Pierre, et al.
Publicado: (2021)

Development of a nomogram for predicting treatment default under facility-based directly observed therapy short-course in a region with a high tuberculosis burden
por: Wang, Saibin
Publicado: (2021)

Addressing TB-related mortality in adults living with HIV: a review of the challenges and potential solutions
por: Sullivan, Amanda, et al.
Publicado: (2022)

PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials
por: Meng, Xiangjiao, et al.
Publicado: (2022)

Synchronous ground‐glass nodules showed limited response to anti‐PD‐1/PD‐L1 therapy in patients with advanced lung adenocarcinoma
por: Wu, Fengying, et al.
Publicado: (2020)

Epistemic modesty, ostentatiousness and the uncertainties of epigenetics: on the knowledge machinery of (social) science
por: Pickersgill, Martyn
Publicado: (2016)

Living well in the Neuropolis
por: Fitzgerald, Des, et al.
Publicado: (2016)

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
por: He, Bingxi, et al.
Publicado: (2020)

An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC)
por: Guo, Haoyue, et al.
Publicado: (2021)

FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III
por: Jiang, Minlin, et al.
Publicado: (2021)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

Diabetic Retinopathy: Battling the Global Epidemic
por: Das, Arup
Publicado: (2016)

Report From the NEI/FDA Diabetic Retinopathy Clinical Trial Design and Endpoints Workshop
por: Nair, Prashant, et al.
Publicado: (2016)

Report From the NEI/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Diseases
por: Csaky, Karl, et al.
Publicado: (2018)

Opportunities from the Center for Perioperative Education
Publicado: (2006)

Opportunities from the Center for Perioperative Education
Publicado: (2006)

Opportunities from the Center for Perioperative Education
Publicado: (2006)

Report From the National Eye Institute Workshop on Neuro-Ophthalmic Disease Clinical Trial Endpoints: Optic Neuropathies
por: Levin, Leonard A., et al.
Publicado: (2021)

Report From the 2022 Mary Tyler Moore Vision Initiative Diabetic Retinal Disease Clinical Endpoints Workshop
por: Levine, S. Robert, et al.
Publicado: (2023)

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2020)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY
por: Bouffet, Eric, et al.
Publicado: (2020)

Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody
por: Song, Xinyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fjfrcgrshq954tt7grv1dn2mip